About this information
Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).
If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.
*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.
Download datasets of the summaries of completed access to information requests.
Found 6686 record(s)
Req # A-2021-000974
Application for AstraZeneca's Covid-19 vaccine ( ChAdOxl-S ). Provide all documents, data, correspondence, or any other item made available to Health Canada by AstraZeneca as of August 20, 2021. Provide all documents received/exchanged/sent by…Organization: Health Canada
February 2025
Req # A-2021-001222
Detailed breakdown of the 2015-2021 government expenditures invested in eliminating all long-term drinking water advisories in First Nation communities by community. Information on the financing pathways; what were the funding approval and…Organization: Health Canada
February 2025
Req # A-2021-001563
All documents regarding any advice or input provided to outside stakeholders on advertising that mentions COVID/coronavirus or related issues, since March 1, 2020.Organization: Health Canada
February 2025
Req # A-2021-001974
Provide the Screening acceptance letter(s) from Health Canada to any and all generic drug manufacturers for any and all Abbreviated New Drug Submissions (ANDS) for the medicinal ingredient dexlansoprazole which appears on the list of Generic Drug…Organization: Health Canada
February 2025
Req # A-2022-000398
The initial cover letters indicating the brand name of the reference drug product and the dosage form of the generic drugs in Health Canada’s list of “Generic Drug Submissions Under Review” dated 2022-06-22 for the medicinal ingredient levetiracetam…Organization: Health Canada
February 2025
Req # A-2022-001491
The initial cover letter indicating the brand name of the reference drug product and the dosage form of the generic drug in Health Canada’s list of “Generic Drug Submissions Under Review” dated 2023-02-24 for the medicinal ingredient levetiracetam.…Organization: Health Canada
February 2025
Req # A-2023-000326
Any correspondence sent or received by Health Canada employees connected with standing offer 6D063-204744 and BTNX, Inc. Timeframe: March 1, 2021 to Nov. 30, 2022. Any reports or briefing notes prepared for or prepared by Health Canada employees…Organization: Health Canada
February 2025
Req # A-2023-000378
The initial cover letter and any other document indicating the brand name of the reference drug product and the dosage form of the generic drug in Health Canada’s list of “Generic Drug Submissions Under Review” dated 2023-06-14 for the medicinal…Organization: Health Canada
February 2025
Req # A-2023-000607
All notes related to the safety and efficacy of the drug being independently reviewed by Health Canada employees who participated in the review the Johnson & Johnson of COVID-19 Vaccine before it was marketed. Any notes that were made to…Organization: Health Canada
February 2025
Req # A-2023-001081
The initial cover letter indicating the brand name of the reference drug product and the dosage form of the generic drug in Health Canada’s list of “Generic Drug Submissions Under Review” dated 2023-10-19 for the medicinal ingredient Liraglutide,…Organization: Health Canada
February 2025